Reclast (Zoledronic Acid) Cost in Maryland 2026

What Does Reclast (Zoledronic Acid) Actually Cost in Maryland?

Zoledronic acid 5 mg IV (brand name Reclast) has a Novartis wholesale acquisition cost near $1,500 per vial, but Maryland patients rarely pay that figure. Retail pharmacies across Maryland average approximately $600 per annual infusion for the generic formulation in 2026. The infusion administration fee, charged separately by the clinic or hospital outpatient department, adds $150 to $400 or more depending on the facility.

Branded Reclast vs. Generic Zoledronic Acid

The FDA has approved multiple generic versions of zoledronic acid 5 mg/100 mL through its ANDA pathway. These generics carry the same active ingredient, same dose, and the same FDA-required bioequivalence standards as branded Reclast. At most Maryland infusion centers, the dispensed product is already a generic, which is why the street price sits far below the Novartis list price.

Branded Reclast is still stocked at some hospital outpatient pharmacies. If your infusion center sources branded product, ask specifically whether a generic substitute is available. The clinical outcome data, including the landmark HORIZON-PFT trial (N=7,765), was generated using the branded formulation, but generic substitution is clinically appropriate per standard bioequivalence principles endorsed by the FDA.

Administration Fees Add to Your Total

The drug vial cost is only part of the bill. Maryland infusion centers charge a separate facility or professional fee for the 15-minute IV infusion. Hospital outpatient departments generally bill higher than independent infusion suites. Patients with high-deductible plans sometimes pay $800 to $1,200 total (drug plus administration) before insurance kicks in. Asking for an itemized estimate before scheduling is standard practice and your right under the No Surprises Act.

Maryland Medicaid Coverage for Reclast (Zoledronic Acid)

Maryland Medicaid ( Maryland Medical Assistance Program) covers zoledronic acid for osteoporosis treatment with a prior authorization requirement. PA criteria typically align with National Osteoporosis Foundation / AACE clinical guidelines, which recommend pharmacotherapy for postmenopausal women and men aged 50 and older with a T-score at or below -2.5, or with a T-score between -1.0 and -2.5 plus a 10-year FRAX major fracture probability at or above 20%.

Prior Authorization Criteria

To obtain PA through Maryland Medicaid, prescribers typically must document:

• A qualifying DXA T-score (usually -2.5 or lower, or -1.0 to -2.5 with elevated FRAX)
• Diagnosis of osteoporosis, glucocorticoid-induced bone loss, or Paget disease of bone
• Failure of or intolerance to oral bisphosphonate therapy in some clinical scenarios
• That the patient cannot self-administer oral therapy (in select cases)

The FDA label for zoledronic acid lists approved indications including postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, Paget disease of bone, and reduction of skeletal events in patients with bone metastases. Maryland Medicaid PA requirements vary by indication, so a prescriber experienced with the program will often simplify approval.

What Medicaid Pays Once Approved

After PA approval, Maryland Medicaid beneficiaries generally pay little to no out-of-pocket cost for the drug itself. Administration fees at participating infusion centers are also covered. Patients receiving care through a Maryland Medicaid managed care organization (MCO) should confirm that their chosen infusion site is in-network, since out-of-network infusion centers may require a separate authorization.

Commercial Insurance Coverage in Maryland

Most Maryland commercial plans, including those sold on the Maryland Health Benefit Exchange, cover zoledronic acid under either the medical benefit or the pharmacy benefit, though the benefit bucket determines your cost-share.

Medical Benefit vs. Pharmacy Benefit

When zoledronic acid is billed under the medical benefit (physician-administered drug, CPT code J3489 or J2430), coinsurance of 10% to 30% applies after the deductible. On a $600 drug cost plus a $300 administration fee, a 20% coinsurance means $180 out of pocket, before any supplemental coverage. When billed under the pharmacy benefit (specialty tier), a flat copay of $50 to $150 is more common.

Ask your plan's member services whether zoledronic acid is on the formulary and which benefit bucket applies. The American College of Clinical Pharmacy has documented wide variability in bisphosphonate formulary placement across commercial plans.

Medicare Part B and Part D in Maryland

Medicare Part B covers physician-administered injectable drugs, including zoledronic acid infusions given in a doctor's office or outpatient hospital. Standard Part B cost-share is 20% after the Part B deductible ($257 in 2026). A Medigap supplement eliminates most of that 20%. Medicare Part D does not typically cover infused drugs administered in a clinical setting, so most Maryland Medicare patients receive zoledronic acid under Part B rather than Part D.

The Centers for Medicare and Medicaid Services (CMS) publishes coverage determinations for infused osteoporosis drugs. Zoledronic acid falls under the National Coverage Determination for osteoporosis drugs when prescribed following a fracture.

Is Compounded Zoledronic Acid Legal in Maryland?

Compounded zoledronic acid is legal in Maryland when prepared by a state-licensed 503A pharmacy and dispensed pursuant to a valid patient-specific prescription from a licensed prescriber. Maryland follows federal law under 21 U.S.C. § 353a, which allows 503A pharmacies to compound drugs for individual patients when specific conditions are met.

503A vs. 503B: What the Difference Means for Patients

A 503A pharmacy compounds for individual patients one prescription at a time. A 503B outsourcing facility compounds in bulk for healthcare facilities. Zoledronic acid for individual outpatient use in Maryland must come from a 503A pharmacy operating under Maryland Board of Pharmacy licensure. The FDA's guidance on compounding specifies that 503A pharmacies may not compound copies of commercially available drugs without a documented clinical reason.

Because FDA-approved generic zoledronic acid is commercially available, a prescriber seeking compounded zoledronic acid for a Maryland patient must provide documentation of a specific clinical need (such as an allergy to an excipient in the commercial product). This is not a barrier that cannot be addressed, but it does require prescriber documentation.

Cost of Compounded Zoledronic Acid in Maryland

When a Maryland 503A pharmacy compounds zoledronic acid and bills through a specialty pharmacy arrangement, some patients report minimal to zero drug cost through certain telehealth or direct-pay programs. The savings come from compounding pharmacy pricing structures rather than manufacturer rebates. Administration fees at the infusion site still apply. Patients should confirm that the compounding pharmacy holds current Maryland Board of Pharmacy licensure before proceeding.

Telehealth Prescribing of Reclast in Maryland

Maryland permits telehealth prescribing of zoledronic acid for established patients. Under Maryland Health General Article § 15-141, telehealth visits are recognized as valid clinical encounters when the prescriber holds a Maryland license and an appropriate prescriber-patient relationship exists.

A telehealth prescriber cannot administer the IV infusion remotely. The workflow is: telehealth visit for evaluation and prescription issuance, then the patient presents to a local Maryland infusion center for the 15-minute infusion. DXA scan results, FRAX scores, and labs (creatinine, calcium) must be available to the prescriber before the prescription is written, this is consistent with the Endocrine Society's 2019 Postmenopausal Osteoporosis Clinical Practice Guideline, which requires baseline renal function assessment before any bisphosphonate is initiated.

Telehealth platforms operating in Maryland must comply with Maryland Health Care Commission telehealth standards. Patients with an estimated GFR below 35 mL/min/1.73 m² are not candidates for zoledronic acid per the FDA label, so creatinine must be checked before prescribing regardless of the visit modality.

Clinical Evidence Supporting Zoledronic Acid Use

The prescribing and cost conversation exists because zoledronic acid has exceptionally strong fracture-reduction data, among the best in the entire bisphosphonate class.

HORIZON-PFT: The Foundational Trial

The HORIZON Key Fracture Trial (N=7,765), published in the New England Journal of Medicine in 2007, randomized postmenopausal women with osteoporosis to zoledronic acid 5 mg IV once yearly or placebo for three years. Zoledronic acid reduced the risk of morphometric vertebral fractures by 70% (3.3% vs. 10.9% in placebo; P<0.001), hip fractures by 41% (1.4% vs. 2.5%; P<0.001), and nonvertebral fractures by 25% (P<0.001).

The trial also demonstrated a mortality benefit: total mortality was 3.3% in the zoledronic acid group vs. 4.5% in placebo (P=0.013), a finding rare among anti-osteoporosis drugs. The NEJM publication remains the primary evidence basis for zoledronic acid's role in osteoporosis management.

HORIZON-RFT: Fracture Prevention After Hip Fracture

The HORIZON Recurrent Fracture Trial (N=2,127) enrolled patients who had recently suffered a low-trauma hip fracture. Zoledronic acid 5 mg IV given within 90 days of surgical repair reduced subsequent clinical fractures by 35% (P=0.001) and reduced all-cause mortality by 28% (P=0.01). This trial is the basis for guidelines recommending bisphosphonate therapy after hip fracture, including recommendations from the American Society for Bone and Mineral Research (ASBMR).

Guideline Support

The Endocrine Society's Clinical Practice Guideline on Postmenopausal Osteoporosis (2019) states: "We recommend treatment with bisphosphonates as first-line therapy for most postmenopausal women with osteoporosis." Zoledronic acid is explicitly listed as a recommended agent given its once-yearly dosing and fracture-reduction profile. The AACE/ACE 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis similarly position zoledronic acid as a high-priority option, particularly for patients with adherence difficulties on weekly oral bisphosphonates.

Safety Profile: What Maryland Patients and Prescribers Should Know

Acute-Phase Reaction

Approximately 31.6% of patients experience an acute-phase reaction (fever, myalgia, arthralgia, headache) within the first three days after the initial infusion, per data from HORIZON-PFT. This drops to roughly 6.6% after the second infusion and 2.8% after the third. Pretreatment with acetaminophen 650 mg every six hours for 72 hours after infusion is the standard clinical approach. The FDA label describes this reaction in full.

Renal Monitoring

The FDA label contraindicates zoledronic acid in patients with creatinine clearance below 35 mL/min. Serum creatinine must be checked before each annual infusion. Infusion should be administered over no less than 15 minutes. Hydration before infusion (500 mL oral fluids) reduces renal risk per standard clinical practice guidelines reviewed in Nephrology Dialysis Transplantation.

Osteonecrosis of the Jaw and Atypical Femur Fracture

Osteonecrosis of the jaw (ONJ) risk with annual IV zoledronic acid for osteoporosis (not oncology dosing) is estimated at fewer than 1 in 10,000 patients per year in population studies reviewed by ASBMR. Atypical subtrochanteric femur fracture risk rises after five or more years of continuous bisphosphonate use. The FDA's 2010 safety communication recommended reassessing continuation at three to five years, a practice now embedded in major guidelines.

Discount Programs and How to Pay Less in Maryland

Manufacturer and Generic Savings Options

Novartis does not maintain a widely accessible retail savings card for Reclast in 2026, but patient assistance programs exist through the Novartis Patient Assistance Foundation for uninsured or underinsured patients who meet income eligibility. Generic zoledronic acid manufacturers do not typically offer branded savings cards, but the price differential versus branded Reclast is already substantial.

GoodRx and Cash-Pay Pharmacy Pricing

GoodRx and similar discount platforms list generic zoledronic acid at Maryland-area pharmacies in a range of $350 to $700 per vial in 2026, depending on pharmacy and location. These discount prices cannot be combined with insurance, you choose one or the other for the drug cost itself.

340B Program Access

Federally Qualified Health Centers (FQHCs) and qualifying hospitals in Maryland participate in the 340B drug pricing program. Eligible patients receiving care at a 340B-covered entity may access zoledronic acid at substantially reduced cost. The Health Resources and Services Administration (HRSA) maintains a searchable list of 340B-covered entities; several operate in Baltimore, Prince George's County, and Montgomery County.

Below is the HealthRX Maryland Zoledronic Acid Cost Decision Framework, developed by the HealthRX medical team for use in clinical intake:

Step 1. Confirm clinical eligibility: DXA T-score, FRAX, serum creatinine, GFR above 35 mL/min/1.73 m². Step 2. Identify insurance type: Maryland Medicaid (seek PA), Medicare Part B (bill J-code, 20% coinsurance), commercial (verify formulary tier and benefit bucket), uninsured. Step 3. For uninsured or high cost-share: check 340B entity access, generic cash-pay pricing, and Novartis Patient Assistance Foundation eligibility. Step 4. If commercial insurance denies or cost-share exceeds $300: evaluate telehealth prescribing with compounded zoledronic acid via a Maryland-licensed 503A pharmacy (requires documented clinical rationale for compounding). Step 5. Select Maryland infusion site: confirm in-network status, get itemized estimate for drug plus administration fee, verify renal labs within 30 days of scheduled infusion.

Dosing, Administration, and Monitoring Reference

Zoledronic acid for osteoporosis is dosed as a single 5 mg IV infusion over no less than 15 minutes, once yearly for treatment or once every two years for prevention of postmenopausal osteoporosis per the FDA label. Adequate calcium and vitamin D supplementation (at least 1,000 mg elemental calcium daily and 800 to 1,000 IU vitamin D daily) should accompany therapy per the Endocrine Society guideline.

Pre-infusion labs to collect:

• Serum creatinine (calculated GFR must exceed 35 mL/min/1.73 m²)
• Serum calcium (correct hypocalcemia before infusion)
• 25-hydroxyvitamin D (treat deficiency before first infusion)

Drug holiday decisions at five years should follow the American Society for Bone and Mineral Research 2022 task force report, which stratifies holiday decisions by hip T-score and fracture history.